Compugen, a provider of predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, has entered into an exclusive license agreement with MedImmune, the global biologics research and development arm of AstraZeneca, for the development of bi-specific and multi-specific immuno-oncology antibody products. Compugen will provide an exclusive license to MedImmune for the development of bi-specific and multi-specific antibody products derived from a Compugen pipeline...